Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype

Bioorganic & Medicinal Chemistry
2012.0

Abstract

The in vitro screening of stereoisomeric bicyclic peptidomimetics towards SAP2 of Candida albicans revealed a constrained chemotype as aspartic protease inhibitor in the micromolar to nanomolar range. The results indicated that the acetal bridge may serve as a transition-state isostere, and that the right match between interactions with subsites and the orientation by hydrogen bonding with Gly85 is the main requisite for inhibitory activity. Molecular docking calculations suggested the bicyclic acetal scaffold to be capable of interacting with the two catalytic aspartic acids, thus resulting in good inhibitory activity with only two hydrophobic groups addressing the enzyme catalytic subsites.

Knowledge Graph

Similar Paper

Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype
Bioorganic & Medicinal Chemistry 2012.0
Identification of constrained peptidomimetic chemotypes as HIV protease inhibitors
European Journal of Medicinal Chemistry 2014.0
Identification of Inhibitors of Drug-Resistant Candida albicans Strains from a Library of Bicyclic Peptidomimetic Compounds
Journal of Medicinal Chemistry 2010.0
Tetracycline-Inducible Expression of Individual Secreted Aspartic Proteases in Candida albicans Allows Isoenzyme-Specific Inhibitor Screening
Antimicrobial Agents and Chemotherapy 2008.0
Targeting fungal virulence factor by small molecules: Structure-based discovery of novel secreted aspartic protease 2 (SAP2) inhibitors
European Journal of Medicinal Chemistry 2020.0
Biomimetic Macrocyclic Inhibitors of Human Cathepsin D: Structure–Activity Relationship and Binding Mode Analysis
Journal of Medicinal Chemistry 2020.0
Cyanobacterial Peptides as a Prototype for the Design of Potent β-Secretase Inhibitors and the Development of Selective Chemical Probes for Other Aspartic Proteases
Journal of Medicinal Chemistry 2012.0
Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Design, chemistry and activity evaluation. Part I
European Journal of Medicinal Chemistry 2009.0
Novel Candida albicans aspartyl protease inhibitor. II. A new pepstatin-ahpatinin group inhibitor,YF-044-D.
The Journal of Antibiotics 1994.0
Structure−Activity Studies of Ground- and Transition-State Analogue Inhibitors of Cyclophilin
Journal of Medicinal Chemistry 2001.0